How Has the Dipeptide Peptidase 4 Inhibitors Market Size Evolved in Recent Years?
The dipeptide peptidase 4 inhibitors market has seen considerable growth due to a variety of factors.
• The dipeptide peptidase 4 inhibitors market has shown strong growth in recent years. It will grow from $11.3 billion in 2024 to $11.92 billion in 2025, at a CAGR of 5.6%.
The growth is driven by better access to diabetes treatments, expanding indications for DPP-4 inhibitors, their increased use in combination therapies, an aging population, and more focus on healthcare and disease prevention.
What Are The Predictions for The Dipeptide Peptidase 4 Inhibitors Market in the Coming Years?
The dipeptide peptidase 4 inhibitors market is expected to maintain its strong growth trajectory in upcoming years.
• The dipeptide peptidase 4 inhibitors market is projected to see steady growth, reaching $14.65 billion by 2029 with a CAGR of 5.3%.
The increase is driven by the rising prevalence of type 2 diabetes, demand for effective management, and the focus on personalized medicine. Major trends include collaborations, product approvals, and R&D efforts.
Which Drivers Are Accelerating Growth In The Dipeptide Peptidase 4 Inhibitors Market?
The increasing prevalence of diabetes is expected to boost the growth of the dipeptide peptidase 4 inhibitors market. Diabetes affects the body’s ability to process glucose, and the number of cases is rising due to sedentary lifestyles and unhealthy diets. Dipeptidyl peptidase 4 inhibitors aid in diabetes management by enhancing glycemic control. For instance, the International Diabetes Federation reported that 537 million adults were living with diabetes in 2021, with that number projected to rise to 783 million by 2045. Therefore, the rising prevalence of diabetes is driving the growth of the dipeptide peptidase 4 inhibitors market.
What Are The Core Segments Of The Global Dipeptide Peptidase 4 Inhibitors Market?
The dipeptide peptidase 4 inhibitors market covered in this report is segmented –
1) By Type: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin, Vildagliptin, Others Types
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Channels
3) By Application: Type 2 Diabetes, Gestational Diabetes, Metabolic Syndrome, Other Applications
Pre-Book The Dipeptide Peptidase 4 Inhibitors Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Who Are the Key Players In The Dipeptide Peptidase 4 Inhibitors Market?
Major companies operating in the dipeptide peptidase 4 inhibitors market are:
• Merck & Co. Inc.
• Novartis AG
• Bristol Myers Squibb Company
• AstraZeneca Plc
• GlaxoSmithKline Plc
• Eli Lilly and Company
• Boehringer Ingelheim International GmbH
• Takeda Pharmaceutical Company Limited
• Daiichi Sankyo Company Limited
• Macleods Pharmaceuticals Ltd.
• Mitsubishi Tanabe Pharma Corp.
• Dr. Reddy's Laboratories Ltd.
• Cipla Limited
• Cadila Healthcare Limited
• Lupin Limited
• Zydus Lifesciences Ltd.
• Glenmark Pharmaceuticals Ltd.
• Aurobindo Pharma Limited
• Alkem Laboratories Ltd.
• Torrent Pharmaceuticals Limited
• Biocon Limited
• LG Life Sciences
• USV Private Limited
• Sanwa Kagaku Kenkyusho Co. Ltd.
• Kowa Company Ltd
What Are The Regional Insights Into The Dipeptide Peptidase 4 Inhibitors Market?
Asia-Pacific was the largest region in the dipeptide peptidase 4 inhibitors market in 2024. Latin America is expected to be the fastest-growing region in the forecast period. The regions covered in the dipeptide peptidase 4 inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
